116 related articles for article (PubMed ID: 35282741)
21. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
[TBL] [Abstract][Full Text] [Related]
22. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
23. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
[TBL] [Abstract][Full Text] [Related]
24. Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Abdel-Mannan OA; Manchoon C; Rossor T; Southin JC; Tur C; Brownlee W; Byrne S; Chitre M; Coles A; Forsyth R; Kneen R; Mankad K; Ram D; West S; Wright S; Wassmer E; Lim M; Ciccarelli O; Hemingway C; Hacohen Y;
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34021056
[TBL] [Abstract][Full Text] [Related]
25. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
26. Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
Bsteh G; Berek K; Hegen H; Teuchner B; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
Mult Scler; 2020 Jan; 26(1):57-68. PubMed ID: 30465490
[TBL] [Abstract][Full Text] [Related]
27. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
JAMA Neurol; 2021 Oct; 78(10):1197-1204. PubMed ID: 34398221
[TBL] [Abstract][Full Text] [Related]
28. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
Teter B; Agashivala N; Kavak K; Chouhfeh L; Hashmonay R; Weinstock-Guttman B
Mult Scler; 2014 Jun; 20(7):830-6. PubMed ID: 24277325
[TBL] [Abstract][Full Text] [Related]
29. Relapses add to permanent disability in relapsing multiple sclerosis patients.
Koch-Henriksen N; Sørensen PS; Magyari M
Mult Scler Relat Disord; 2021 Aug; 53():103029. PubMed ID: 34116481
[TBL] [Abstract][Full Text] [Related]
30. Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study.
Bawand R; Ghiasian M; Fathoallahi N; Moradi A
Mult Scler Relat Disord; 2022 Jul; 63():103857. PubMed ID: 35597079
[TBL] [Abstract][Full Text] [Related]
31. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
Kunchok A; Lechner-Scott J; Granella F; Trojano M; Alroughani R; Sola P; Ferraro D; Lugaresi A; Onofrj M; Ozakbas S; Izquierdo G; Grammond P; Luis Sanchez-Menoyo J; Van Wijmeersch B; Boz C; Pucci E; McCombe P; Grand'Maison F; Spitaleri D; Vucic S; Hupperts R; Jokubaitis V; Sormani MP; Butzkueven H; Kalincik T;
Mult Scler; 2021 Apr; 27(5):695-705. PubMed ID: 32639855
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
33. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
[TBL] [Abstract][Full Text] [Related]
34. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
35. Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis.
Bsteh G; Hegen H; Altmann P; Berek K; Auer M; Zinganell A; Di Pauli F; Rommer P; Leutmezer F; Deisenhammer F; Berger T
Mult Scler J Exp Transl Clin; 2020; 6(3):2055217320945738. PubMed ID: 32922831
[TBL] [Abstract][Full Text] [Related]
36. How patients with multiple sclerosis acquire disability.
Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
[TBL] [Abstract][Full Text] [Related]
37. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.
Salavisa M; Serrazina F; Ladeira AF; Correia AS
Clin Neurol Neurosurg; 2023 Feb; 225():107612. PubMed ID: 36701940
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
39. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
40. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
